These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample preparation platform and their next generation sample to answer clinical molecular diagnostic platform.
John Steuart, managing director of Arcxis Biotechnologies, said: “Claremont Creek Ventures is excited about the ongoing investment in Arcxis which will help the company bring this important new technology to clinical molecular laboratories around the world.”